<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908137</url>
  </required_header>
  <id_info>
    <org_study_id>1000070281</org_study_id>
    <nct_id>NCT04908137</nct_id>
  </id_info>
  <brief_title>Use of 2-Octyl Cyanoacrylate (Dermabond) in Neonatal Circumcision: A Randomized Controlled Trial</brief_title>
  <official_title>Use of 2-Octyl Cyanoacrylate (Dermabond) in Neonatal Circumcision: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Description: 2-Octyl Cyanoacrylate (Dermabond) use in neonatal circumcision are being&#xD;
      practiced to prevent complications; however, no randomized controlled trials was ever done to&#xD;
      assess efficacy and safety. This is a single-centered, randomized clinical trial to assess&#xD;
      the efficacy and safety of 2-Octyl Cyanoacrylate (Dermabond) application in neonatal&#xD;
      circumcision to prevent complication.&#xD;
&#xD;
      Primary Objective: To determine the efficacy and safety of 2-Octyl Cyanoacrylate (Dermabond)&#xD;
      application versus control in neonatal circumcision to prevent post-procedural complication.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To assess post-procedural pain score difference between with versus without 2-Octyl&#xD;
           Cyanoacrylate (Dermabond) application in neonatal circumcision&#xD;
&#xD;
        2. To assess parents' satisfaction and cosmesis post-neonatal circumcision with versus&#xD;
           without 2-Octyl Cyanoacrylate (Dermabond) application.&#xD;
&#xD;
      Endpoints: Primary Endpoint: Complication rates post-neonatal circumcision within 180 days&#xD;
      with the following complication in specific or in composite ‚¶Å Bleeding requiring hemostatic&#xD;
      intervention (suturing, dermabond application, silver nitrite application, pressure bandage)&#xD;
&#xD;
        -  Infection requiring antibiotic administration or wound drainage&#xD;
&#xD;
        -  Excess skin as assessed by parents satisfaction&#xD;
&#xD;
        -  Meatal stenosis&#xD;
&#xD;
        -  Adhesion requiring surgical correction.&#xD;
&#xD;
      Secondary Endpoints:&#xD;
&#xD;
        1. pain score within 5 min and 30 minutes postneonatal circumcision using the FLACC score&#xD;
           by parents and MBPS scale by a medical allied personnel.&#xD;
&#xD;
        2. Parents satisfaction as determined by a simple 10-score liked scale and cosmesis&#xD;
           assessment scale within 24hrs and within 30 days post-neonatal circumcision.&#xD;
           Complication rates detailed above in specific time points clustered according to (within&#xD;
           24 hrs, within 2 weeks, within 30 days, within 30 to 180 days).&#xD;
&#xD;
      Study Population: 280 male neonates (140 each intervention groups) who are eligible for&#xD;
      neonatal circumcision with no other medical co-morbidities.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      2-Octyl Cyanoacrylate (Dermabond) 0.5ml/ sticks) topical application around post-circumcision&#xD;
      site subcoronal area.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complication rates (Composite)</measure>
    <time_frame>180 days post neonatal circumcision</time_frame>
    <description>Composite complication rates post-neonatal circumcision within 180 days following neonatal circumcision</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score (FLACC) by Parents</measure>
    <time_frame>5 minutes and 30 minutes</time_frame>
    <description>pain score within 5 minutes post-neonatal circumcision using the FLACC score by parents. (Higher Score is Worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score (MBPS) by Medical Personnel</measure>
    <time_frame>5 minutes and 30 minutes</time_frame>
    <description>pain score within 5 minutes and 30 minutes post-neonatal circumcision using the MBPS scale by a medical allied personnel. (Higher Score is Worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parents Satisfaction</measure>
    <time_frame>within 24 hours and 30 days post neonatal circumcision</time_frame>
    <description>Parents satisfaction as determined by a simple 10-score liked scale and cosmetic assessment scale within 24hours and within 30 days post-neonatal circumcision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rates (specific case characteristics)</measure>
    <time_frame>within 24 hours, within 2 weeks, within 30 days within 30 to 180 days</time_frame>
    <description>Complication rates post-neonatal circumcision</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Redundant Prepuce</condition>
  <arm_group>
    <arm_group_label>2-Octyl Cyanoacrylate (Dermabond) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-Octyl Cyanoacrylate (Dermabond) 0.5ml/ sticks topical application around post-circumcision site subcoronal area immediately after the circumcision devise is removed and circumcision procedure was done</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>will receive Vaseline cream application around the post-circumcision site immediately after circumcision</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2-octyl cyanoacrylate</intervention_name>
    <description>Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D &amp; C Violet No. 2. It is provided as a single use applicator in a blister package</description>
    <arm_group_label>2-Octyl Cyanoacrylate (Dermabond) Group</arm_group_label>
    <other_name>Dermabond</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consent provided by one of the parents&#xD;
&#xD;
          -  Male sex eligible for neonatal circumcision (with no genital anomalies, such as&#xD;
             hypospadias components or congenital curvatures)&#xD;
&#xD;
          -  Aged 2 to 60 days&#xD;
&#xD;
          -  In good general health as evidenced by medical history&#xD;
&#xD;
          -  No history of hematological diseases with clotting or bleeding disorders such as&#xD;
             hemophilia, Von Willebrand diseases&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An individual who meets any of the following criteria will be excluded from&#xD;
             participation in this study:&#xD;
&#xD;
               -  Presence of bleeding or clotting disorders&#xD;
&#xD;
               -  Family history of bleeding or clotting disorder&#xD;
&#xD;
               -  Genital anomalies such as hypospadias, severe ventral curvatures&#xD;
&#xD;
               -  Known allergic reactions to components of the 2-Octyl Cyanoacrylate (Dermabond)&#xD;
&#xD;
               -  Febrile illness within 48hrs&#xD;
&#xD;
               -  Any condition or diagnosis, that could in the opinion of the Principal&#xD;
                  Investigator or the delegate interfere with the participant's ability to comply&#xD;
                  with study instructions, might confound the interpretation of the study results,&#xD;
                  or put the participant at risk.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael E Chua, MD</last_name>
    <phone>4168136899</phone>
    <email>michael.chua@sickkids.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Baker</last_name>
      <phone>4168136917</phone>
      <email>katie.baker@sickkids.ca</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Pannozzo, RN</last_name>
      <phone>4168136917</phone>
      <email>urology.nurses@sickkids.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Joana Dos Santos, MD FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Michael Chua</investigator_full_name>
    <investigator_title>Staff Urologist</investigator_title>
  </responsible_party>
  <keyword>Circumcision</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

